Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2026)

Royalty Pharma has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $9.3 billion for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 11.59% year-over-year to $9.3 billion; the TTM figure through Jun 2026 stood at $9.3 billion (up 11.59% YoY), while the FY2025 annual figure was $9.3 billion, up 18.55% from the prior year.
• Total Non-Current Liabilities came in at $9.3 billion for Q2 2026 at Royalty Pharma, up from $9.2 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $9.3 billion in Q4 2025 to a low of $6.3 billion in Q3 2023.
• Average Total Non-Current Liabilities over 5 years is $7.8 billion, with a median of $7.8 billion recorded in 2024.
• Year-over-year, Total Non-Current Liabilities dropped 13.62% in 2023 and grew 24.96% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $7.3 billion in 2022, then decreased by 13.57% to $6.3 billion in 2023, then advanced by 24.96% to $7.9 billion in 2024, then grew by 18.55% to $9.3 billion in 2025, then declined by 0.08% to $9.3 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $9.3 billion in Q2 2026, $9.2 billion in Q1 2026, and $9.3 billion in Q4 2025.